Cilostazol in Acute Ischemic Stroke Treatment (CAIST)
The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke
Sponsor: Korea Otsuka International Asia Arab Co., Ltd.
This PHASE4 trial investigates Cerebral Infarction and is currently completed. Korea Otsuka International Asia Arab Co., Ltd. leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jan 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Korea Otsuka International Asia Arab Co., Ltd.
- Korea Otsuka Pharmaceutical Co., Ltd.
- Seoul National University Boramae Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Ahnyang, South Korea
- • Daejeon, South Korea
- • Incheon, South Korea
- • Koyang, South Korea
- • Koyang, Kyunggi Province, South Korea
- • Seoul, South Korea
- • Sungnam, South Korea